Palvella director gets 6,000 stock options grant
Palvella Therapeutics director Matthew Pauls received a grant of stock options representing rights to buy 6,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Palvella Therapeutics director Matthew Pauls received a grant of stock options representing rights to buy 6,000 shares of common stock. The options have an exercise price of 154.84 per share and expire on June 29, 2036. They vest in 36 equal monthly installments, conditioned on his continued service, and his derivative holdings after this grant total 6,000 options.
Insider Trade Summary
Grant/Award: 6,000 shares
Grant/Award
1 txn
Insider
Pauls Matthew
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 6,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 6,000 contracts (Direct)
Footnotes (1)
- F1. The options vest in 36 equal monthly installments, subject to the Reporting Person's continued service as of each such vesting date.
Key Figures
Options granted: 6,000 options
Exercise price: 154.84 per share
Expiration date: June 29, 2036
+2 more
5 metrics
Options granted
6,000 options
Stock Option (Right to Buy) grant to director Matthew Pauls
Exercise price
154.84 per share
Exercise price of granted stock options
Expiration date
June 29, 2036
Expiration of the granted stock options
Vesting schedule
36 monthly installments
Vesting conditioned on continued service
Derivative holdings after grant
6,000 options
Total options held following the transaction
Key Terms
Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, vesting
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
exercise price financial
"conversion_or_exercise_price: "154.8400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The options vest in 36 equal monthly installments, subject to the Reporting Person's continued service"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Palvella Therapeutics (PVLA) report for Matthew Pauls?
Palvella Therapeutics reported that director Matthew Pauls received a grant of stock options for 6,000 shares of common stock. This is a compensation-related award, not an open-market purchase or sale of shares.
How many Palvella Therapeutics (PVLA) stock options were granted to Matthew Pauls?
Matthew Pauls was granted stock options covering 6,000 shares of Palvella Therapeutics common stock. These options are a derivative security giving him the right to buy shares if he meets the vesting and exercise conditions.
What is the exercise price and expiration date of Matthew Pauls’ PVLA stock options?
The granted stock options have an exercise price of 154.84 per share and expire on June 29, 2036. Pauls must exercise the options before that expiration date to acquire the underlying common shares.
How do Matthew Pauls’ Palvella Therapeutics (PVLA) options vest over time?
The options vest in 36 equal monthly installments, subject to Matthew Pauls’ continued service on each vesting date. This means a portion becomes exercisable each month over three years as long as he remains in service.
Is Matthew Pauls’ Form 4 transaction in PVLA an open-market buy or sell?
The Form 4 shows a grant of stock options, categorized as a grant, award, or other acquisition. It is not an open-market buy or sell; it represents compensation that may later be exercised into common shares.
How many Palvella Therapeutics (PVLA) options does Matthew Pauls hold after this grant?
Following the reported grant, Matthew Pauls holds 6,000 stock options directly. These options relate to Palvella Therapeutics common stock and become exercisable over time according to the 36-month vesting schedule.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates